title: Renal transplantation at the University of Pittsburgh: the impact of FK506.
abstract: 1. In an unselected adult renal transplant population, FK506 as the primary immunosuppressive agent yielded one- and 2-year actuarial patient survival rates of 95% and 93% and one- and 2-year actuarial graft survival rates of 89% and 83%, respectively. Forty-nine percent of successfully transplanted patients were weaned off steroids. 2. In pediatric renal transplant patients, FK506 has been associated with 100% one- and 3-year actuarial patient survival rates and 98% and 85% one- and 3-year actuarial graft survival rates, respectively. Sixty-two percent of successfully transplanted patients were taken off prednisone, with dramatic improvements in height. 3. FK506 has been used successfully in rescuing 70-74% of adult or pediatric renal transplant patients with an acute rejection that failed conventional therapy. 4. Kidney/bone marrow transplantation under FK506 therapy has been successfully performed without graft-versus-host disease and with routine augmentation of chimerism. 5. The side effects of FK506 included nephrotoxicity, neurotoxicity, and diabetogenicity; they were comparable to those seen with CsA. 6. FK506 is an important new addition to the immunosuppressive armamentarium in renal transplant patients.
authors.affiliation: University of Pittsburgh, School of Medicine, Pittsburgh Transplantation Institute, Pennsylvania, USA.
authors.forename: R
authors.initials: R
authors.lastname: Shapiro
authors.forename: M
authors.initials: M
authors.lastname: Jordan
authors.forename: V P
authors.initials: VP
authors.lastname: Scantlebury
authors.forename: C
authors.initials: C
authors.lastname: Vivas
authors.forename: H A
authors.initials: HA
authors.lastname: Gritsch
authors.forename: A S
authors.initials: AS
authors.lastname: Rao
authors.forename: M
authors.initials: M
authors.lastname: Trucco
authors.forename: A
authors.initials: A
authors.lastname: Zeevi
authors.forename: A J
authors.initials: AJ
authors.lastname: Demetris
authors.forename: P
authors.initials: P
authors.lastname: Randhawa
mesh_terms: D000206:Actuarial Analysis; D000293:Adolescent; D000328:Adult; D000368:Aged; D016026:Bone Marrow Transplantation / Q000706:statistics & numerical data; D002648:Child; D002675:Child, Preschool; D002678:Chimera; D005260:Female; D006082:Graft Enhancement, Immunologic; D006084:Graft Rejection / Q000453:epidemiology / Q000517:prevention & control; D006785:Hospitals, University / Q000706:statistics & numerical data; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007223:Infant; D016381:Islets of Langerhans Transplantation / Q000706:statistics & numerical data; D016030:Kidney Transplantation / Q000401:mortality / Q000706:statistics & numerical data*; D008297:Male; D008875:Middle Aged; D010414:Pennsylvania / Q000453:epidemiology; D016032:Randomized Controlled Trials as Topic; D012189:Retrospective Studies; D016019:Survival Analysis; D015996:Survival Rate; D016559:Tacrolimus / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D007166:Immunosuppressive Agents; D016559:Tacrolimus